Loading...
•
Sep 30, 2023
Harmony Biosciences Q3 2023 Earnings Report
Harmony Biosciences demonstrated strong financial performance in Q3 2023, marked by revenue growth and strategic pipeline expansion.
Key Takeaways
Harmony Biosciences reported a strong Q3 2023, with net product revenues reaching $160.3 million, a 37% increase compared to the same period in 2022. The company also expanded its pipeline through the acquisition of Zynerba Pharmaceuticals and initiated a new $200 million share repurchase program.
Net product revenues for Q3 2023 reached $160.3 million, up 37% year-over-year.
Average number of patients on WAKIX increased by approximately 350 sequentially to approximately 5,800.
GAAP net income for Q3 2023 was $38.5 million, or $0.63 earnings per diluted share.
Expanded pipeline with acquisition of Zynerba Pharmaceuticals; Zygel in Pivotal Phase 3 Trial for Fragile X syndrome
Revenue by Segment
Forward Guidance
Harmony Biosciences is focused on advancing its pipeline and expanding its market presence. They are on track for several key milestones, and actively pursuing new indications for pitolisant.
Positive Outlook
- Remain Committed and Continue to Pursue Idiopathic Hypersomnia Indication
- Expect to initiate the TEMPO study in the first quarter of 2024.
- On track for topline data from the Myotonic Dystrophy (DM1) Phase 2 proof-of-concept signal detection trial in the fourth quarter of 2023.
- On track to submit a supplemental new drug application (sNDA) for a pediatric narcolepsy indication to the FDA in the fourth quarter of 2023.
- Advancing new pitolisant based formulations into the clinic in the fourth quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...